A phase I trial of temsirolimus with the Akt inhibitor, perifosine, for recurrent pediatric solid tumors including gliomas and medulloblastomas, was well tolerated, although partial or complete responses were not achieved [320]. Here, AKT1 is linked to central nervous system cancer.